News from American Association of Corporate Optometrists, Eyes on EyeCare, EyeSouth Partners, Mojo Vision, and Prevent Blindness.
Practice Tip: With the new year comes a sense of excitement for learning about and doing new things to improve patient care. Austin Lifferth, OD, FAAO, “Glaucoma” columnist, innovated in 2021 by looking at the IOP measurements after he examined the optic nerve. “Such a simple sequence shift helps me look at the nerve more objectively and helps ensure that I place the IOP measurements in the context of the optic nerve — rather than the optic nerve examination in the context of the IOP measurements.” With January also “Glaucoma Awareness Month,” it makes sense to give this a shot. See https://www.optometricmanagement.com/issues/2021/november-december-2021/how-your-colleagues-are-innovating.
American Association of Corporate Optometrists Announces 2022 Annual Conference
The American Association of Corporate Optometrists announced their 2022 Annual Conference, scheduled for May 20 to May 22, 2022, in Nashville, at the Gaylord Opryland Resort. While specific agenda information is yet to be released, attendees at the in-person event can expect 16 hours of CE, expert speakers, networking events, and more. Visit https://www.aacoeyes.org/annual-conference-2022.
Eyes On EyeCare Releases 2021 Report on Optometric Profession
Eyes On Eyecare, formerly CovalentCareers, released its 2021 Optometrist report. Specifically, the report covers salary, employment, finances, innovations and technology, the future of the profession, and more, based on what 708 respondents, including practice owners, practicing optometrists, and students had to say. To download the report, visit https://eyesoneyecare.com/resources/2021-optometrist-report/.
EyeSouth Partners Completes Affiliation with Clayton Eye Center
EyeSouth Partners, an eye care-focused management services organization backed by Shore Capital Partners that is committed to partnering with leading physicians to build a premier network of eye care services in the U.S., has completed an affiliation with Clayton Eye Center. Clayton Eye Center is led by Dr. Joon Kim and provides a full array of routine eye care and surgical procedures. The affiliation is EyeSouth’s eleventh in Georgia. EyeSouth’s affiliate network is comprised of 27 practices that have over 230 doctors providing medical and surgical eye care services at over 120 locations. Visit www.eyesouthpartners.com.
Mojo Vision Smart Contact Lens to Join Forces With Sports and Fitness Brands
Mojo Vision announced strategic partnerships with Adidas Running (running/training), Trailforks (cycling, hiking/outdoors), Wearable X (yoga), Slopes (snow sports), and 18Birdies (golf) to collaborate on ways to improve access to data and enhance athletes’ performance during sporting activities via Mojo Vision’s smart contact lens. Learn more about Mojo Vision at https://mojo.vision.
Prevent Blindness Marks National Glaucoma Awareness Month with Patient Resource Program
Prevent Blindness is launching a package of free educational resources to support glaucoma patients and their caregivers. January is National Glaucoma Awareness month, and the organization is marking it with a new episode of the Focus on Eye Health Expert Series, featuring glaucoma expert Constance Okeke, MS, MCSE, and Jeff Todd, CEO, and president of Prevent Blindness. Also being offered is “The Glaucoma Community,” an app and website that has more than 1800 members, designed in partnership with Responsum Health. The digital package includes access to financial assistance programs, support groups, live chat, personalized newsfeed, and educational content in seven languages.
Stuart Therapeutics Announces Topline Results of Dry Eye Disease Clinical Trial
Stuart Therapeutics, Inc. announced the topline results of its first Phase 2 clinical trial for its lead drug candidate, ST-100, in dry eye disease patients. The topical eyedrop met its primary endpoint – Schirmer's Test Responder Rate (defined as a statistically significant difference between the percentage of patients achieving a 10 mm increase or more in Schirmer's tear test scores) at 28 days (p=0.0266). In the randomized, controlled, double-masked trial, ST-100 also demonstrated significant positive results in several symptoms and ocular surface staining scores as early as treatment day seven in both the intent to treat population, and the treated patient sub-populations, reports the company.
O.D. Notebook is published weekly on Wednesdays. Unless otherwise noted, the information presented is based on press releases and/or announcements by the respective organizations. Find earlier editions here. To submit a press release to be considered for publication, click here. Additionally, find frequently updated COVID-19 coverage here.